Novavax (NVAX) shares plummeted 5.03% in pre-market trading on Friday following a significant price target cut by JPMorgan. The healthcare company's stock faced immediate pressure after the investment bank lowered its price target on Novavax to $7 from $9, maintaining an Underweight rating on the shares.
JPMorgan's decision to reduce the price target comes despite Novavax's Q2 performance beating expectations. However, the details of the earnings beat and JPMorgan's specific concerns were not fully disclosed in the available information. The maintained Underweight rating suggests that the investment bank continues to hold a pessimistic view on Novavax's near-term prospects.
This price target reduction could signal broader concerns about Novavax's future performance and may influence other investors' perceptions of the stock. As the trading day progresses, it remains to be seen how this pre-market plunge will impact Novavax's overall performance and whether other analysts will adjust their outlooks on the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.